New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
05:55 EDTABMD, ABMD, ABMD, ANGO, ANGO, ANGO, BAX, BAX, BAX, BDX, BDX, BDX, CAH, CAH, CAH, COV, COV, COV, EW, EW, EW, NVO, NVO, NVO, SYK, SYK, SYKSociety of Thoracic Surgeons to hold annual meeting
49th Annual Meeting of the STS is being held in Los Angeles on January 26-30.
News For ABMD;ANGO;BAX;BDX;CAH;COV;EW;NVO;SYK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
12:50 EDTSYKSmith & Nephew, Stryker seen as potential headliners of 2015 M&A, TheDeal says
Subscribe for More Information
February 26, 2015
18:44 EDTNVONovo Nordisk receives Health Canada approval for Saxenda
Subscribe for More Information
11:50 EDTCAHCardinal Health management to meet with William Blair
Subscribe for More Information
February 24, 2015
07:31 EDTCAHRBC Capital to hold a conference
Subscribe for More Information
February 23, 2015
09:08 EDTBAXBaxter announces Illinois headquarters for biopharmaceutical spin-off
Subscribe for More Information
February 22, 2015
12:51 EDTCAHJ&J considers Cordis sale with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
February 20, 2015
17:31 EDTCAHJ&J considering sale of Cordis with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
15:09 EDTBDXBecton Dickinson management to meet with JPMorgan
Meetings to be held in New York on February 24 and in Atlanta on February 25 hosted by JPMorgan.
12:02 EDTNVOEmisphere says Novo Nordisk completes Phase 2 OG217SC trial
Emisphere Technologies (EMIS) highlighted positive Phase 2 data from Eligen licensee Novo Nordisk (NVO) pertaining to OG217SC, the oral formulation of semaglutide, a long-acting human GLP-1 analogue that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. OG217SC is provided in a tablet formulation with an absorption-enhancing excipient, SNAC. SNAC is included in the Eligen Carrier Concept. Novo Nordisk announced that it has successfully completed the phase 2 trial for OG217SC, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks. Results of the study are available on Novo Nordisk's website. Based on these results, Novo Nordisk announced that it will initiate consultations with regulatory authorities subsequent to which a decision of whether to progress OG217SC into phase 3 development will be made. Under its GLP-1 License Agreement, Novo Nordisk is working to develop and commercialize oral formulations of its proprietary GLP-1 receptor agonists in combination with Emisphere carriers. Under the GLP-1 License Agreement, Emisphere could receive additional contingent product development and sales milestone payments and would also be entitled to receive royalties in the event Novo Nordisk commercializes products developed under such Agreement. Under the GLP-1 License Agreement, Novo Nordisk is responsible for the development and commercialization of the products.
08:27 EDTSYKStryker has a conference call hosted by JPMorgan
Subscribe for More Information
07:08 EDTBAXAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
18:25 EDTBAXPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
February 17, 2015
17:02 EDTSYKSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
15:15 EDTBDXBecton Dickinson management to meet with William Blair
Subscribe for More Information
09:29 EDTCOVMedtronic says FY16 constant currency revenue may be up mid-single digit range
Subscribe for More Information
09:27 EDTCOVMedtronic, Covidien targeting over $850M in cost synergies through FY18
Subscribe for More Information
08:49 EDTCOVMedtronic sees being at high end of Q4 revenue growth range
Subscribe for More Information
08:00 EDTABMDAbiomed price target raised to $72 from $60 at Leerink
Subscribe for More Information
08:00 EDTABMDAbiomed price target raised to $72 from $60 at Leerink
Leerink raised its price target for Abiomed shares to $72 saying it believes recent adoption momentum is sustainable as the company continues to penetrate the emergent and high risk percutaneous coronary intervention patient population. It reiterates an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use